Search
2,3-Dihydroxy-5-Oxo-Hexanedioate
go.drugbank.com/drugs/DB03237ExperimentalSynonyms: 2,3-Dihydroxy-5-Oxo-Hexanedioate8-Bromo-Adenosine-5'-Monophosphate
go.drugbank.com/drugs/DB03349ExperimentalSynonyms: 8-Bromo-Adenosine-5'-MonophosphateN-Pyridoxyl-Threonine-5-Monophosphate
go.drugbank.com/drugs/DB03576ExperimentalSynonyms: N-Pyridoxyl-Threonine-5-MonophosphatePyridoxal-5'-Phosphate-N-Oxide
go.drugbank.com/drugs/DB03629ExperimentalSynonyms: Pyridoxal-5'-Phosphate-N-Oxide6-aza uridine 5'-monophosphate
go.drugbank.com/drugs/DB03718ExperimentalSynonyms: 6-aza uridine 5'-monophosphate, 6-Azauridine-5'-monophosphateCategories: Heterocyclic Compounds, 1-RingDicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSynonyms: (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acidEtripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigationalEtripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsSynonyms: Methyl 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]benzoate, Benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl esterDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigationalDordaviprone is a first-in-class small molecule imipridone. On August 6, 2025, dordaviprone was granted accelerated approval by the FDA. … Factor 4 (ATF4), and induction of endoplasmic reticulum (ER) stress response.
Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-oneCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InducersRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. … Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesSynonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateEtoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalA semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. … Etoposide acts primarily in the G2 and S phases of the cell cycle.
Synonyms: 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)International brands: Vepesid K